Jpmorgan Chase & CO Nymox Pharmaceutical Corp Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$0.19 - $0.49 $470 - $1,212	2,475 Added 31.96%	10,219 $1,000
Q1 2023 May 11, 2023	SELL	$0.33 - $0.5 $531 - $805	-1,611 Reduced 17.22%	7,744 $2,000
Q4 2022 Feb 13, 2023	SELL	$0.28 - $0.74 $80 - $213	-289 Reduced 3.0%	9,355 $3,000
Q3 2022 Nov 14, 2022	BUY	$0.22 - $0.61 $84 - $233	383 Added 4.14%	9,644 $4,000
Q2 2022 Aug 11, 2022	SELL	$0.38 - $1.41 $831 - $3,085	-2,188 Reduced 19.11%	9,261 $4,000
Q1 2022 May 11, 2022	SELL	$1.21 - $2.0 $764 - $1,264	-632 Reduced 5.23%	11,449 $14,000
Q4 2021 Feb 10, 2022	SELL	$0.95 - $2.1 $94 - $207	-99 Reduced 0.81%	12,081 $15,000
Q3 2021 Nov 12, 2021	BUY	$1.3 - $2.23 $15,834 - $27,161	12,180 New	12,180 $25,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.